



## Cumulative Index 2002

### Volume 28

February	GENETICS, pages 1–180
May	REGIONAL MANAGEMENT OF FIBROMYALGIA, pages 181–460
August	PEDIATRIC RHEUMATOLOGY, pages 461–722
November	IDIOPATHIC INFLAMMATORY MYOPATHIES, pages 723–1030

Note: Page numbers of article titles are in **bold face** type.

### A

- Acanthosis nigricans, in dermatomyositis, 592
- Acetaminophen, for fibromyalgia syndrome, 268
- Acid maltase deficiency, clinical features of, 767
- Activities of daily living, assessment of in fibromyalgia syndrome, 208 in inflammatory myopathy, 947–948
- Acupuncture, for fibromyalgia syndrome, 300, 358
- S-Adenosylmethionine, for fibromyalgia syndrome, 266, 373
- Adhesion molecules, in inflammatory myopathy, 797, 799, 808
- Adrenal gland dysfunction, in fibromyalgia syndrome, 391–394
- Adrenocorticotrophic hormone, abnormal, in fibromyalgia syndrome, 392–393
- Aerobic conditioning, for fibromyalgia syndrome, 428–429
- Affected sibling pair studies, in rheumatoid arthritis, 3, 7–9
- Affective disorders in fibromyalgia syndrome, 270 substance P inhibitors for, 336–337
- Alanine aminotransferase, measurement of, in inflammatory myopathy, 866–867
- Aldolase, measurement of, in inflammatory myopathy, 866
- Alendronate, for osteoporosis in juvenile rheumatoid arthritis, 518 in pediatric rheumatic diseases, 471
- Alkaline phosphatase, bone-specific, as metabolism marker, 655
- Allodynia in fibromyalgia syndrome, 235 in pediatric patients, 671
- Alprazolam, for fibromyalgia syndrome, 266, 426
- Alternative marker-disease association hypothesis, in rheumatoid arthritis, 40
- Alternative therapy, for fibromyalgia syndrome, 300–301
- Alveolitis fibrosing, in inflammatory myopathy, 832 in inflammatory myopathy, 992–993
- Amantadine, for fibromyalgia syndrome, 373
- American College of Rheumatology, juvenile rheumatoid arthritis classification of, 503–504
- Aminoacyl-tRNA synthetases, antibodies to, myopathy and, 814–816, 834, 994–995
- Amitriptyline, for fibromyalgia syndrome, 245, 273–274, 277–278, 371 exercise implications of, 424 in fatigue, 266 in sleep disorders, 359
- Amyloid deposition, in inflammatory myopathy, 793–794

- Amyopathic dermatomyositis, 833-834  
    familial, 894  
    juvenile, 853-854
- Anakinra, for pediatric rheumatic diseases, 473
- Androgens, fibromyalgia syndrome related to, 396-397
- Anemia  
    in fibromyalgia syndrome, 361  
    in Kawasaki disease, 631-632
- Aneurysms, coronary artery, in Kawasaki disease, 632-634
- Angiitis, primary, of central nervous system, 627-628
- Angiography, in vasculitis, 626
- Animal models, of myositis. *See* Myositis, animal models of.
- Ankylosing spondylitis, juvenile-onset, 543-544
- Ankylosing tarsitis, juvenile-onset, 546-547
- Antibiotics, for spondyloarthritis, 548-549
- Antibody(ies). *See also* Autoantibodies; *specific antibodies.*  
    in inflammatory myopathy, 814-816  
    synthetase, myopathy in, 814-816, 834
- Anticardiolipin antibodies, in systemic lupus erythematosus, 569
- Antidepressants, for fibromyalgia syndrome, 189, 273-275, 441-442  
    exercise implications of, 424  
    in fatigue component, 371  
    in mood disorders, 278-279  
    in pain, 244-247  
    in sleep disorders, 321-322, 359
- Antiepileptic drugs, for fibromyalgia syndrome, 248-249
- Antineoplastic agents, tumor susceptibility to, transcript array analysis of, 166
- Antineutrophil cytoplasmic antibodies  
    in Churg-Strauss syndrome, 646-647  
    in Henoch-Schönlein purpura, 642  
    in microscopic polyangiitis, 646  
    in Wegener's granulomatosis, 644-646
- Antinuclear antibodies  
    in dermatomyositis, 586  
    in fibromyalgia syndrome, 213-214  
    in idiopathic musculoskeletal pain, 673  
    in inflammatory myopathy, 871  
    in systemic lupus erythematosus, 569
- Antispasticity agents, for fibromyalgia syndrome, 249
- Antisynthase antibodies, in inflammatory myopathy, 868, 873-878
- Antisynthetase syndrome, 814-816, 834, 994-995
- Apheresis, for inflammatory myopathy, 991
- Apnea, sleep, in fibromyalgia syndrome, 189, 356, 361-362
- Apolipoprotein E, defects of, in inflammatory myopathy, 898-899
- Arteritis, Takayasu's, in pediatric patients, 626-627
- Arthralgia, in inflammatory myopathy, 833
- Arthritis  
    enthesitis-related, 506  
    in Churg-Strauss syndrome, 647  
    in Henoch-Schönlein purpura, 639  
    in juvenile dermatomyositis, 851  
    in Kawasaki disease, 631  
    in spondyloarthritis, 535-537  
    in systemic lupus erythematosus, 565  
    psoriatic, juvenile-onset, 506, 544-545  
    reactive, 542-543  
    rheumatoid, juvenile. *See* Juvenile rheumatoid arthritis.  
    septic, versus juvenile rheumatoid arthritis, 509-512
- Arthritogenic peptides, in rheumatoid arthritis, 22
- Aspartate aminotransferase, measurement of, in inflammatory myopathy, 866-867
- Aspirin  
    for Kawasaki disease, 465-466, 634  
    for pediatric rheumatic diseases, 465-466
- Association studies, in rheumatoid arthritis, 3-4
- Asthma, in Churg-Strauss syndrome, 647
- Autoantibodies  
    in myopathy, 814-816, 868-884, 994-995  
    in scleroderma, 609-610  
    in systemic lupus erythematosus, 564, 569  
    in systemic sclerosis, 681  
    in vasculitis, 623-624
- Autoimmune disorders  
    in fibromyalgia syndrome, 409, 414  
    in inflammatory myopathy, 728-729
- Autonomic nervous system disorders of. *See* Dysautonomia.  
    evaluation of, 380-383  
    function of, 379-380
- Avascular necrosis, in systemic lupus erythematosus, 568

- Azathioprine  
for inflammatory myopathy,  
987-990, 993  
for pediatric rheumatic diseases, 467, 474  
Henoch-Schönlein purpura, 644  
juvenile rheumatoid arthritis, 522  
systemic lupus erythematosus,  
561-563

**B**

- B lymphocytes, transcript array analysis of,  
159-160  
Back pain, in pediatric patients, 671-672  
Baclofen, for fibromyalgia syndrome, 249  
Balance, exercises for, in fibromyalgia  
syndrome, 430, 432  
Barthel Score, in inflammatory myopathy, 948  
Becker muscular dystrophy, versus  
inflammatory myopathy, 746-747,  
749-750  
Benzodiazepines, for fibromyalgia syndrome,  
248-249, 277  
Beta blockers, for fibromyalgia syndrome,  
276, 425  
Biofeedback, for fibromyalgia syndrome,  
300, 358  
Biopsy, muscle. *See* Muscle(s), biopsy of.  
Bisphosphonates, for osteoporosis  
in juvenile rheumatoid arthritis, 518, 661  
in pediatric rheumatic diseases,  
470-471  
in systemic lupus erythematosus, 567  
Bladder irritation, in fibromyalgia syndrome,  
193, 280, 410, 414-415  
Bleeding, gastrointestinal, in  
Henoch-Schönlein purpura, 639-640  
Bohan and Peter classification, of  
inflammatory myopathies, 838-840  
Bone  
development of, in pediatric rheumatic  
diseases, 463-464  
loss of. *See* Osteoporosis.  
metabolism of, in pediatric rheumatic  
diseases, 653-665. *See also*  
Osteoporosis.  
biochemical markers of, 655  
bone density measurement, 567,  
657-658  
bone function and composition,  
653-654  
cellular elements, 654

- juvenile rheumatoid arthritis,  
658-661  
normal growth, 656-657

- Bone scan, in idiopathic musculoskeletal  
pain, 673  
Bowel motility disorders, substance P  
inhibitors for, 337  
Brain  
pain transmission in, in fibromyalgia  
syndrome, 187  
systemic lupus erythematosus  
manifestations in, 563-565  
Brancher deficiency, clinical features of, 767  
Breast cancer, transcript array analysis of,  
164-165  
Bromazepam, for fibromyalgia syndrome, 266  
Bronchoalveolar lavage, in inflammatory  
myopathy, 953  
Bupropion, for fibromyalgia syndrome, 247,  
275, 279  
Bursitis, in fibromyalgia syndrome, 211, 310

**C**

- C protein, for myositis induction, 925-926  
Caffeine, for fibromyalgia syndrome, 279  
Calcification, in dermatomyositis, 589-591  
Calcinosis, in dermatomyositis, 831,  
847-848, 855  
Calcitonin  
for fibromyalgia syndrome, 266  
for osteoporosis, in systemic lupus  
erythematosus, 567  
Calcium  
for osteoporosis  
in juvenile rheumatoid arthritis, 518  
in pediatric rheumatic diseases,  
656-657  
in systemic lupus  
erythematosus, 567  
in bone, 653  
Campylobacter infections, reactive arthritis in,  
542-543  
Cancer  
in inflammatory myopathy, 729-732  
in juvenile dermatomyositis, 853  
myositis in, 833  
transcript array analysis of, 162-166  
versus juvenile rheumatoid arthritis,  
510-513

- Candidate gene approach, to susceptibility loci search  
in osteoarthritis, 103-105  
in rheumatoid arthritis, 5-6
- Capillary vasculopathy  
in inflammatory myopathy, 813-814  
nailfold, in dermatomyositis, 844-846
- Carbidopa/levodopa, for fibromyalgia syndrome, 425
- Carbohydrate metabolism, in myopathies, 759-764
- Carbonic anhydrase III, measurement of, in inflammatory myopathy, 866-867
- Cardiovascular disorders, in Kawasaki disease, 632-633
- Carisoprodol, for fibromyalgia syndrome, 278, 425
- Carnitine deficiency, myopathy in, 767-768
- Carpal tunnel syndrome, in fibromyalgia syndrome, 313
- cDNA, in transcript array analysis.  
See Transcript array analysis.
- Central nervous system. *See also* Brain; Spinal cord.  
Henoch-Schönlein purpura manifestations in, 640  
pain pathways in, 236-244  
primary angiitis of, 627-628  
systemic lupus erythematosus manifestations in, 563-565
- Central sensitivity syndromes, in fibromyalgia syndrome, 193, 206, 280, 421
- Chagas' disease, inflammatory myopathy in, 908
- Chemokines, in inflammatory myopathy, 809, 811-813
- Chemotherapy, tumor susceptibility to, transcript array analysis of, 166
- Chest pain, in fibromyalgia syndrome, 408-409, 413
- Chiari malformation, fibromyalgia syndrome with, 211-212
- Chilblains, musculoskeletal pain in, 676
- Childhood Arthritis Health Profile, 515
- Childhood Health Assessment Questionnaire, 495  
in inflammatory myopathy, 947-948, 964  
in juvenile rheumatoid arthritis, 514
- Childhood Health Questionnaire, in inflammatory myopathy, 967
- Childhood Myositis Assessment Scale, 946-947
- Chimerism, in inflammatory myopathy, 897
- Chiropractic, for fibromyalgia syndrome, 300
- Chlamydia* infections, reactive arthritis in, 542
- Chlorambucil, for inflammatory myopathy, 989
- Chlorpromazine, for fibromyalgia syndrome, 360
- Chondrocytes, gene therapy directed to, in rheumatoid arthritis, 141-142
- Chromosomes, shortening of, by telomerase activity, in rheumatoid arthritis, 86-87
- Chronic fatigue syndrome, fibromyalgia syndrome overlap with. *See* Fatigue, in fibromyalgia syndrome.
- Churg-Strauss syndrome, in pediatric patients, 646-647
- Ciguatera poisoning, myositis in, 904
- Circadian pacemaker, in fibromyalgia syndrome, 398-399
- Citalopram, for fibromyalgia syndrome, 246, 266, 274, 371
- CJ-11974 (substance P inhibitor), for fibromyalgia syndrome, 339
- Clodronate, for osteoporosis, in pediatric rheumatic diseases, 471
- Clonazepam, for fibromyalgia syndrome, 277-278, 413-414  
exercise implications of, 425  
in sleep disorders, 189, 361, 385
- Clonidine, for fibromyalgia syndrome, 249
- Cognitive-behavioral therapy, for fibromyalgia syndrome, 443  
in fatigue component, 298  
in sleep disorders, 358
- Cognitive dysfunction  
in fibromyalgia syndrome, 191, 205, 282  
in systemic lupus erythematosus, 564
- COL* genes, mutations of, in osteoarthritis, 101-107
- Colchicine, for dermatomyositis, 994
- Cold intolerance, in fibromyalgia syndrome, 193, 282

- Collagen**  
bovine, inflammatory myopathy related to, 904  
degradation products of, as bone metabolism markers, 655  
in bone, 654
- Compartment syndrome, chronic, musculoskeletal pain in, 676**
- Complement deficiency, systemic lupus erythematosus in, 570**
- Complementary and alternative therapy, for fibromyalgia syndrome, 300-301**
- Complex regional pain syndrome**  
in fibromyalgia syndrome, 408-409, 414  
prognosis for, 679-680
- Computed tomography**  
in systemic lupus erythematosus, 565  
of lung, in inflammatory myopathy, 953  
quantitative, in bone density measurement, 658
- Continuous positive air pressure, for sleep disorders, in fibromyalgia syndrome, 361**
- Coping, with arthritis, quality of life and, 496**
- Coronary artery aneurysms, in Kawasaki disease, 632-634**
- Corticosteroids**  
for fibromyalgia syndrome, 373  
for inflammatory myopathy, 984, 986-987  
for juvenile dermatomyositis, 856  
for pediatric rheumatic diseases, 467-470  
dermatomyositis, 593  
Henoch-Schönlein purpura, 642-643  
juvenile rheumatoid arthritis, 516, 519-520  
Kawasaki disease, 635  
polyarteritis nodosa, 637  
spondyloarthritis, 548-549  
systemic lupus erythematosus, osteopenia due to, 566-568  
Wegener's granulomatosis, 645-646
- Corticotropin-releasing hormone, hyperactivity of, in fibromyalgia syndrome, 391-394**
- Cortisol deficiency, in fibromyalgia syndrome, 391-394**
- Costochondritis, in fibromyalgia syndrome, 310**
- Coxsackievirus**  
for myositis induction, 927  
juvenile dermatomyositis and, 584
- CP122721 (substance P inhibitor), for nausea and vomiting, 336**
- Creatine, measurement of, in inflammatory myopathy, 867, 871**
- Creatine kinase, measurement of**  
in inflammatory myopathy, 733-734, 863-866, 949-950  
in metabolic myopathy, 769
- Crohn's disease, arthropathy of, 545-546**
- Cubital tunnel syndrome, in fibromyalgia syndrome, 313**
- Cyclobenzaprine, for fibromyalgia syndrome, 245, 266, 371**  
exercise implications of, 425  
in sleep disorders, 278, 359
- Cyclophosphamide**  
for inflammatory myopathy, 989, 993  
for pediatric rheumatic diseases, 467, 473-474  
Henoch-Schönlein purpura, 644  
juvenile rheumatoid arthritis, 523  
microscopic polyangiitis, 646  
polyarteritis nodosa, 637  
systemic lupus erythematosus, 561-563  
systemic sclerosis, 617  
Wegener's granulomatosis, 646
- Cyclosporine**  
for inflammatory myopathy, 989, 993  
for juvenile rheumatoid arthritis, 522  
for pediatric rheumatic diseases, 467, 475  
for spondyloarthritis, 548-549
- Cystitis, interstitial, in fibromyalgia syndrome, 314, 410, 414**
- Cytokines. *See also specific cytokines.***  
genes for, in rheumatoid arthritis, 82, 88-89  
in dermatomyositis, 587  
in hypothalamic-pituitary-adrenal axis regulation, fibromyalgia syndrome and, 393  
in inflammatory myopathy, 797, 799, 809, 811-813, 817-818, 898-899  
in scleroderma, 610-611  
produced by T helper cells, in inflammation, 156-159

**D**

- Deconditioning, in fibromyalgia syndrome, exercise for, 190-191**
- Dehydroepiandrosterone, fibromyalgia syndrome related to, 396-397**

- Dendritic cells  
for myositis induction, 926  
transcript array analysis of, 160-161
- Depression, in fibromyalgia syndrome,  
189-190, 278-279
- Dermatomyositis  
amyopathic, 833-834, 894  
animal models of. *See* Myositis, animal  
models of  
arthralgia in, 833  
autoantibodies in. *See* Inflammatory  
myopathy(ies), autoantibodies in.  
calcinosis in, 831  
cancer in, 729-732, 833  
clinical features of, 827-831  
diagnostic criteria for, 734-736  
epidemiology of, 727  
familial, 894  
histochemistry of, 791-792  
immunopathology of, 792  
juvenile. *See* Juvenile dermatomyositis.  
pathology of, 782-785, 789-792  
pulmonary involvement in, 832  
rash in, 827-831, 993-994  
ulcerative course, 848-849  
weakness in, 832
- Dermatomyositis sine myositis, 833-834
- Desipramine, for fibromyalgia syndrome, 274
- Desquamation, in Kawasaki disease, 631
- Dextromethorphan, for fibromyalgia  
syndrome, 344-345, 347-348
- Diaphyseal dysplasia, progressive,  
musculoskeletal pain in, 676
- Diclofenac, for pediatric rheumatic diseases,  
465-466
- Diet, inflammatory myopathy related to,  
902-904
- Diltiazem, for dermatomyositis, 994
- Diphenhydramine, for fibromyalgia  
syndrome, 359
- Dipyridamole, for Henoch-Schönlein  
purpura, 644
- Discoid lupus, 561
- Dizziness, in fibromyalgia syndrome, 193,  
281-282
- DNA  
antibodies to, in systemic lupus  
erythematosus, 569  
in transcript array analysis. *See* Transcript  
array analysis.  
naked, for myositis induction, 926-927
- Dolasetron, for fibromyalgia syndrome,  
320-321
- L-Dopa/carbidopa, for fibromyalgia  
syndrome, 189
- Dorsal horn neurons, pain transmission in,  
in fibromyalgia syndrome, 186-187,  
237-240
- Doxepin, for fibromyalgia syndrome, 245,  
274, 278
- Drug(s), inflammatory myopathy related to,  
902-904
- Dual-energy X-ray absorptiometry, for  
osteopenia, 657-658  
in systemic lupus erythematosus, 567
- Duchenne muscular dystrophy  
expression profiling in, 751-755  
versus inflammatory myopathy,  
746-747, 749-750, 753-756
- Dysautonomia  
in fibromyalgia syndrome, 281, 379-387  
assessment of, 380-383  
circadian disturbance, 356  
pathophysiology of, 379-380,  
383-384  
treatment of, 190, 384-385  
in idiopathic musculoskeletal  
pain, 671
- Dyserlin deficiency, myopathy in, versus  
inflammatory myopathy, 744-747
- Dyspareunia, in fibromyalgia syndrome,  
410-411
- Dyspepsia, nonulcer, in fibromyalgia  
syndrome, 409
- Dysphagia  
in inflammatory myopathy, 832-833,  
951-952, 983-984, 994  
in juvenile dermatomyositis, 850
- Dysphoria, in fibromyalgia syndrome,  
278-279
- Dyspnea, in inflammatory myopathy, 832
- Dystrophic myopathy, versus inflammatory  
myopathy, 743-758  
dyserlin deficiency, 744-747  
dystrophinopathy, 746-747, 749-750,  
753-756  
expression profiling in, 751, 753-756  
merosin deficiency, 747-748, 750-752
- E**
- Echocardiography, in inflammatory myopathy,  
953-954

- Echoviruses, inflammatory myopathy related to, 906
- Education  
in transitions for children with special health care needs and disabilities, 691-696  
patient, on fibromyalgia syndrome, 295-296, 368-370, 439-441
- Elbow, epicondylitis of, in fibromyalgia syndrome, 307, 309
- Electroacupuncture, for fibromyalgia syndrome, 300
- Electroencephalography, in sleep disorders, in fibromyalgia syndrome, 353-357
- Electromyography  
in inflammatory myopathy, 959, 962  
in metabolic myopathy, 771
- Electron microscopy, in metabolic myopathy, 774
- Emotional reactions, in fibromyalgia syndrome, 270
- Employment, in transitions for children with special health care needs and disabilities, 691-696
- En coup de sabre, in scleroderma, in pediatric patients, 602-604, 607
- Endocrine dysfunction, in fibromyalgia syndrome, 190, **389-404**  
growth hormone insulin-like growth factor-I axis, 395-396  
hypothalamic-pituitary-adrenal axis, 281, 391-394  
melatonin, 398-399  
model of, 389-390  
prolactin, 398  
sex hormones, 396-398  
thyroid, 394-395
- Endomysial inflammation, in inflammatory myopathy, 784, 786-787, 793
- Endothelial markers, for inflammatory myopathy, 956-961
- Enteroviruses  
for myositis induction, 927  
in inflammatory myopathy, 905-906
- Enthesitis  
in arthritis, 506  
in spondyloarthritides, 537-539
- Enthesopathy, in fibromyalgia syndrome, 307, 309-310
- Entrapment neuropathy, in fibromyalgia syndrome, 313
- Environmental factors  
in inflammatory myopathy, 900-909  
dietary supplements, 902-904  
drugs, 902-904  
epidemiology and, 900-902  
food, 902-904  
infections, 905-909  
vaccination, 904  
in juvenile dermatomyositis, 582-583  
in rheumatoid arthritis, 4
- Eosinophilia, in Churg-Strauss syndrome, 647
- Eosinophilia myalgia syndrome, 903-904
- Eosinophilic fasciitis, versus systemic sclerosis, 682
- Epicondylitis, in fibromyalgia syndrome, 307, 309
- Epistasis (gene-gene interactions), in rheumatoid arthritis, 72
- Epstein-Barr virus infection, systemic lupus erythematosus and, 568
- Erythema, in dermatomyositis, 829, 846-847
- Erythromelalgia, musculoskeletal pain in, 676
- Esophagitis  
in inflammatory myopathy, 833  
in juvenile dermatomyositis, 850  
in systemic sclerosis, 617, 681
- Etanercept  
for juvenile rheumatoid arthritis, 522-523  
for pediatric rheumatic diseases, 467, 472-473  
for spondyloarthritides, 548-549
- Ethnic differences, in rheumatoid arthritis, 19-20, 42-45  
shared epitope hypothesis and, 62-67
- European Spondyloarthropathy Study Group, criteria of, 534-535
- Exercise  
for fibromyalgia syndrome, 190-191, 298, 370, **419-436**  
aerobic conditioning in, 428-429  
balance improvement, 430, 432  
endocrine function and, 399-400  
evaluation for, 422  
flexibility training in, 429-430, 432-434  
individualization of, 422  
interventions for, 420-421  
low-intensity, 421  
medication interactions with, 424-426  
pain and fatigue in, 430-431  
prescription for, 427-431

- principles of, 421-422
  - pros and cons, 419-420
  - strength training in, 427-428, 432-434
  - timing of, within treatment program, 422, 427
  - for idiopathic musculoskeletal pain, 678-679
  - for inflammatory myopathy, 983
- Exercise testing, in inflammatory myopathy, 947
- Existential crisis, in fibromyalgia syndrome, 191-192
- Extremities, abnormalities of, differential diagnosis of, imaging in, 487-488
- Eye disorders, in juvenile dermatomyositis, 852-853
- 
- F**
- Fabry disease, musculoskeletal pain in, 675-676
- Familial Mediterranean fever, in pediatric patients, 647-648
- Familial myositis, 894
- Fatigue, in fibromyalgia syndrome, **367-378**, 406-407
  - causes of, 187
  - definition of, 367-368
  - evaluation of, 202-203, 368-369
  - post-exercise, 190-191
  - treatment of, 187-188, 279-280, 369-374, 413
- Feedback, physiological, in fibromyalgia syndrome treatment, 293-294
- Feline immunodeficiency virus, for myositis induction, 928
- Felty's syndrome, human leukocyte antigens and, 25
- Fever, differential diagnosis of, imaging in, 484-487
- Fibroblasts, cell cycle regulation of, transcript array analysis of, 154-155
- Fibromyalgia syndrome
  - autoimmune disorders in, 409, 414
  - chest pain in, 408-409, 413
  - classification of, 202
  - clinic for, 438-439
  - clinical features of, 383-384
  - cold intolerance in, 193, 282
  - complexity of, 201-202
  - conditions concomitant with, 192-193, 205, 208-209, 280-282, **405-417**

- conditions overlapping with, 204, 206
- diagnosis of, 181-182, 212-213
- differential diagnosis of, 212-213
- dizziness in, 193, 281-282
- downward spiral in, 220
- dysautonomia with. *See* Dysautonomia, endocrine dysfunction in, 190, **389-404**
- evaluation of, 439
  - fatigue component, 262-263, 368-369
  - follow-up, 214-215
  - for exercise prescription, 423
  - history in, 201-209
  - laboratory, 213-214
  - medical, **201-218**
  - physical examination in, 209-214
  - psychological, 204, 207, **219-233**
- fatigue in. *See* Fatigue, in fibromyalgia syndrome.
- headache in. *See* Headache, in fibromyalgia syndrome.
- irritable bladder syndrome with, 193, 280, 410, 414-415
- irritable bowel syndrome with, 192-193, 206, 280, 409-410, 414
- Lyme disease and, 411-412, 414
- misinformation on, 441
- mood disorders in, 278-279
- multiple sensitivities in, 193, 206, 282, 421
- multisystem nature of, 383-384
- office management of, **437-446**
- outlook for, 442-443
- pathophysiology of
  - neuroendocrine perturbations in, 389-404
  - substance P in, 329-331
- patient education on, 295-296, 368-370, 439-441
- prognosis for, patient educational level and, 182-183
- psychological factors in. *See* Psychological factors, in fibromyalgia syndrome.
- quality of life in, evaluation of, 204, 207-208
- radiologic evaluation of, 213-214
- reflex sympathetic dystrophy in, 408-409, 414
- relieving factors in, 206-207
- restless legs syndrome in, 206, 278, 355, 361-362, 410
- sleep disorders in. *See* Sleep disorders, in fibromyalgia syndrome.
- subgroups of, 202
- substance P measurements in, 331-332
- support groups for, 441
- symptoms of, 202-206
- temporomandibular joint dysfunction with, 281, 407, 413



- treatment of, **181-199**, 412-415  
  advanced, 442-443  
  analgesics for, **235-259**  
  autoimmune conditions, 414  
  cognitive-behavioral, 296-298, 370-371  
  cognitive dysfunction, 282  
  cold intolerance, 193, 282  
  complementary and alternative, 300-301  
  dizziness, 193, 281-282  
  dysautonomia, 281  
  endocrine dysfunction, 281  
  evaluation of, 193-194  
  exercise for. *See* Exercise, for fibromyalgia syndrome.  
  fatigue symptoms, 279-280, 369-374, 413  
  headache, 415  
  history of, 205, 209  
  irritable bladder syndrome, 280, 410, 414-415  
  irritable bowel syndrome, 280, 409-410, 414  
  N-methyl-D-aspartate receptor antagonists in, **343-351**  
  migraine headache, 280-281, 411  
  mood disorders, 278-279  
  multicomponent, 299  
  multiple sensitivities, 282  
  neuropharmacology of, **235-259**  
  nonpharmacologic, **291-304**  
  options for, 440-444  
  pain. *See* Pain, in fibromyalgia syndrome.  
  patient education for, 295-296, 368-370, 439-441  
  pharmacologic, **261-290**  
  physician-patient relationship in, 444  
  principles of, 263-265  
  self-management framework for, 292-294  
  side effects of, 264  
  sleep disorders, 188-189, 277-278  
  substance P inhibitors in, **329-342**  
  temporomandibular joint dysfunction, 281  
  triage process for, 438-439  
  triggering factors in, 204, 206-207
- 56kd antigen, antibodies to, in inflammatory myopathy, 869, 883
- Flexibility training, for fibromyalgia syndrome, 429-430, 432-434
- Fludarabine, for inflammatory myopathy, 988-989
- Fludrocortisone, for fibromyalgia syndrome, 373, 385
- Fluoxetine, for fibromyalgia syndrome, 266, 273, 275, 371-372
- Food, inflammatory myopathy related to, 902-904
- Foot  
  ankylosing tarsitis of, 546-547  
  plantar fasciitis of, in fibromyalgia syndrome, 310
- Forearm ischemic exercise test, in metabolic myopathy, 770-771
- Functional assessment, in inflammatory myopathy, 946-948
- 
- ## G
- Gait abnormalities, differential diagnosis of, imaging in, 488-490
- Gamma globulin, for dermatomyositis, 593
- Gamma-hydroxybutyrate, for fibromyalgia syndrome, 188-189, 278, 374
- Gastrointestinal manifestations  
  of Henoch-Schönlein purpura, 639-640  
  of inflammatory myopathy, 832-833, 994  
  of juvenile dermatomyositis, 850
- Gender differences, in rheumatoid arthritis, human leukocyte antigens and, 24, 43, 47
- Gene therapy, for rheumatoid arthritis. *See* Rheumatoid arthritis, gene therapy for.
- Genetics  
  of familial Mediterranean fever, 647-648  
  of inclusion body myositis, 793, 899-900  
  of inflammatory myopathy, 893-900  
    assessment of, 893-894  
    chimerism in, 897  
    familial myositis, 894  
    human leukocyte antigens in.  
      *See under* Human leukocyte antigens.  
    inclusion body, 793, 899-900  
    non-HLA genes in, 898-899  
    T-cell receptors in, 899  
  of juvenile dermatomyositis, 583-588, 751, 753  
  of Kawasaki disease, 629-630  
  of metabolic myopathies, 774-775  
  of muscular dystrophy, 751-756  
  of osteoarthritis, **95-109**  
  of rheumatoid arthritis  
    components of, **1-15**

- gene therapy, 127-149
  - juvenile, 508-509
  - outcome and, 39-58
  - prognosis and, 17-37
  - severity and, 59-78
  - target tissue and, 79-94
  - of systemic lupus erythematosus, 111-126
  - transcript array analysis in, 151-176
- Genome-wide scan, in osteoarthritis, 105-107
- Genotoxicity, in inflammation, in rheumatoid arthritis, 83-84
- Gingival inflammation, in juvenile dermatomyositis, 849-850
- Glomerulonephritis
- in Henoch-Schönlein purpura, 640, 643-644
  - in microscopic polyangiitis, 646
  - in systemic lupus erythematosus, 561-563
- Glycogenoses, 763, 766-767, 774
- Gold salts, for pediatric rheumatic diseases, 469
- Gottron's papules, in dermatomyositis, 827, 829, 844
- GR205171 (substance P inhibitor), for affective disorders, 336
- Graft-versus-host disease
- inflammatory myopathy related to, 905
  - versus systemic sclerosis, 682
- Granisetron, for fibromyalgia syndrome, 320
- Granulomatosis
- in sarcoidosis, 647
  - in Wegener's granulomatosis, 644-646
- Granzyme, in inflammatory myopathy, 810, 815
- Growth disturbances
- in pediatric rheumatic diseases, 462-463
  - in systemic lupus erythematosus, 567
  - localized, in juvenile rheumatoid arthritis, 516
- Growth hormone deficiency, in fibromyalgia syndrome, 190, 281, 360, 395-396
- H**
- Hand(s), mechanic's, in dermatomyositis, 849-850, 877
- Headache
- in fibromyalgia syndrome, 206, 408, 411
  - migraine, 280-281, 313-314, 411
  - treatment of, 313-314, 415
  - substance P inhibitors for, 337-338
- Health Assessment Questionnaire, in inflammatory myopathy, 964
- Health-related quality of life
- in inflammatory myopathy, 966-967
  - in pediatric patients, with arthritis, 493-501
  - coping and, 496
  - definition of, 493-494
  - health status domains in, 495-498
  - impact of, 498
  - methodologic issues in, 494
  - pain and, 496
  - physical function and, 495
  - psychosocial adjustment and, 497
  - rheumatoid, 514-515
  - social functioning and, 497-498
- Heart disorders
- in fibromyalgia syndrome, 408, 413
  - in inflammatory myopathy, 833
  - in juvenile dermatomyositis, 851-852
- Heart rate variability analysis, in fibromyalgia syndrome, 380, 382-383
- Heliotrope rash, in dermatomyositis, 829, 841, 844
- Hemophagocytic lymphohistiocytosis syndrome, in juvenile rheumatoid arthritis, 518-519
- Henoch-Schönlein purpura, in pediatric patients, 638-644
- antineutrophil cytoplasmic antibodies in, 642
  - arthritis and arthralgia in, 639
  - central nervous system involvement in, 640
  - clinical features of, 638
  - cutaneous manifestations of, 638-639
  - diagnosis of, 641
  - epidemiology of, 638
  - gastrointestinal involvement in, 639-640
  - genitourinary involvement in, 640
  - kidney involvement in, 640, 643-644
  - pulmonary involvement in, 641
  - treatment of, 642-644
- Hepatitis B
- inflammatory myopathy in, 909
  - juvenile dermatomyositis in, 585-586
- Hepatitis C, inflammatory myopathy in, 909
- HLAs. *See* Human leukocyte antigens.
- Hormones, in systemic lupus erythematosus development, 560-561

- hprt* gene mutations, in rheumatoid arthritis, 85
- 5-HT<sub>3</sub> receptor antagonists, for fibromyalgia syndrome, 244, 247, 249-250, 276, 279, 319-328  
clinical studies of, 321-324  
in irritable bowel syndrome, 187, 193  
mechanism of action of, 319-321
- Human immunodeficiency virus infection, inflammatory myopathy and, 799, 906-907
- Human leukocyte antigens  
in inflammatory myopathy, 807-810, 878, 895-898  
in juvenile dermatomyositis, 583-584, 587-588  
in rheumatoid arthritis, 17-37  
arthritogenic peptides presentation and, 22  
clinical course and, 18-19, 24-25  
complex associations in, 19-21  
diagnostic use of, 23-24  
epidemiology of, 18  
erosive synovitis and, 18-19, 25-31  
extra-articular manifestations and, 25  
gender differences in, 24, 43, 47  
heterogeneity and, 39-58  
case-control studies of, 42-50  
cohort studies of, 50-52  
risk factors for, 39-41  
juvenile, 508-509  
pathogenic concepts and, 21-23  
prognostic use of, 18, 23-24  
rheumatoid factor in, 24-25, 49-50  
shared epitope hypothesis for. *See* Shared epitope hypothesis.  
T-lymphocyte receptor repertoire and, 22-23  
target tissue considerations in, 79-81  
treatment response and, 31-32  
in spondyloarthritides, 532-533, 537, 540-544, 546-547
- Human parvovirus B19 infection  
inflammatory myopathy and, 908-909  
systemic lupus erythematosus and, 568
- Human T-cell lymphotropic virus infections, inflammatory myopathy and, 799, 906-907
- Humoral immunity  
in dermatomyositis, 586-587  
in inflammatory myopathy, 814-816
- Hydrocortisone, for fibromyalgia syndrome, 373
- Hydrodolasetron, for fibromyalgia syndrome, 320
- Hydroxy-methylglutamate coenzyme A reductase inhibitors, inflammatory myopathy related to, 903
- Hydroxychloroquine  
for dermatomyositis, 994  
for pediatric rheumatic diseases, 467-469
- 5-Hydroxytryptophan  
for fibromyalgia syndrome, 320, 359-360  
type 3 receptor antagonists of. *See* 5-HT<sub>3</sub> receptor antagonists.
- Hyperalgesia, in fibromyalgia syndrome, 235
- Hypermobility, musculoskeletal pain in, 674
- Hyperprolactinemia, in fibromyalgia syndrome, 398
- Hypersensitivity vasculitis, versus Henoch-Schönlein purpura, 641
- Hyperthyroidism, musculoskeletal pain in, 677
- Hypotension, orthostatic, in fibromyalgia syndrome, 380-383, 408
- Hypothalamic-pituitary-adrenal axis, dysfunction of, in fibromyalgia syndrome, 190, 281, 391-394
- Hypothyroidism  
in fibromyalgia syndrome, 190, 281, 394-395  
musculoskeletal pain in, 677
- Hypoxia, muscle, in inflammatory myopathy, 817
- 
- I**
- Ibuprofen  
for fibromyalgia syndrome, 266  
for pediatric rheumatic diseases, 465-466
- Idiopathic juvenile osteoporosis, musculoskeletal pain in, 676-677
- Imipramine, for fibromyalgia syndrome, 274
- Immune globulin, intravenous  
for dermatomyositis, 994  
for inflammatory myopathy, 990-991, 994  
for pediatric rheumatic diseases, 471-472

- dermatomyositis, 593
- juvenile rheumatoid arthritis, 522
- Kawasaki disease, 633-634
- Immune system
  - in inflammatory myopathy, 805-819
  - in pediatric rheumatic diseases, 464-466, 586-588
- Immunization. *See* Vaccination.
- Immunodeficiency
  - rheumatic disease and, 463-465
  - systemic lupus erythematosus in, 569-570
- Immunoglobulin(s), defects of, in inflammatory myopathy, 898
- Immunologic markers, for inflammatory myopathy, 956-961
- Immunosuppressive therapy.
  - See also specific drugs.*
  - for inflammatory myopathy, 987-990
  - for pediatric rheumatic diseases, 467, 473-476
  - for polyarteritis nodosa, 637
  - for Wegener's granulomatosis, 645-646
- Inclusion body myositis
  - animal models for, 930
  - autoantibodies in, 872-873
  - clinical features of, 834
  - diagnostic criteria for, 737-738
  - electron microscopy of, 794-795
  - epidemiology of, 723, 727
  - familial, 894
  - genetics of, 899-900
  - histochemistry of, 793-794
  - histology of, 834
  - immunopathology of, 797, 799
  - in infections, 905
  - pathogenesis of, 819
  - pathology of, 784, 787-789, 793-795, 797-799
  - retrovirus infections with, 799
- Indomethacin, for pediatric rheumatic diseases, 465-466
- Infantile polymyositis (merosin deficiency), versus inflammatory myopathy, 747-748, 750-752
- Infections
  - cellular transcriptional response to, 161-162
  - in inflammatory myopathy, 905-909
  - in systemic lupus erythematosus, 568-569
  - Kawasaki disease in, 629
  - scleroderma in, 612
  - versus juvenile rheumatoid arthritis, 509-513
- Inflammation, in rheumatoid arthritis, genotoxicity of, 83-84
- Inflammatory bowel disease, arthropathy of, 545-546
- Inflammatory myopathy(ies). *See also specific diseases, e.g., Juvenile dermatomyositis.*
  - animal models of. *See* Myositis, animal models of.
  - assessment of, 937-977. *See also* Inflammatory myopathy(ies), laboratory testing in.
  - ancillary measures for, 942-943, 955-961
    - electromyography, 959, 962
    - imaging, 944, 955, 958
    - immunologic markers, 956-961
    - muscle biopsy, 959, 962
  - core set measures for, 939-954
    - comprehensive, 954
    - extraskeletal muscle disease activity, 950-954
    - global assessment, 940-942
    - magnetic resonance imaging, 944
    - muscle-associated enzyme activity, 943, 948-950
    - muscle strength, 941-942, 944-945
    - myometry, 942
    - nail fold capillaroscopy, 943
    - physical function, 942-944, 946-948
  - disease damage, 962-966
  - general principles of, 937-938
  - health-related quality of life, 966-967
  - international consensus on, 966
  - autoantibodies in, 868-884
    - antinuclear, 871
    - antisynthase, 868, 873-878
    - myositis-associated, 869, 881-883
    - myositis-specific, 868-869, 871-881
    - new, 870, 883-884
    - usefulness of testing, 884
  - autoimmune diseases with, 728-729
  - cancer with, 729-732
  - classification of, 578-580, 732-733
  - clinical features of, 765, **827-836**
    - cancer-associated, 833
    - cardiac, 833
    - dermatologic, 827-831
    - gastrointestinal, 832-833
    - in antisynthetase syndrome, 834
    - inclusion body, 834
    - joint, 833
    - muscular, 831-832
    - pulmonary, 832

- diagnosis of, 577-578. *See also*  
    Inflammatory myopathy(ies),  
    laboratory testing in,  
    criteria for, 733-738
- differential diagnosis of, 580-581,  
    **743-758**
- disability in, 996-997
- disorders associated with, 728-732
- epidemiology of, 723-728, 900-902
- expression profiling in, 751, 753-756
- genetics of, 893-900  
    assessment of, 893-894  
    chimerism in, 897  
    familial myositis, 894  
    human leukocyte antigens in. *See*  
        under Human leukocyte  
        antigens.  
    inclusion body, 793, 899-900  
    non-HLA genes in, 898-899  
    T-cell receptors in, 899
- historical overview of, 577-581
- laboratory testing in, **861-891**  
    autoantibodies in, 868-884  
    muscle-derived factors in,  
        861-867  
        creatinine, 867, 871  
        creatinine kinase, 733-734,  
            863-866, 949-950  
        myoglobin, 769, 867,  
            949-950  
        troponin, 867, 871, 949
- muscle biopsy in, **781-802**
- natural history of, 995-996
- pathogenesis of, **803-826**  
    animal models of, 804  
    cellular mechanisms in, 805-814  
    chemokines in, 809, 811-813  
    cytokines in, 797, 799, 809, 811-  
        813, 817-818  
    historical studies of, 805  
    humoral mechanisms in, 814-816  
    inclusion body, 819  
    major histocompatibility complex  
        molecules in, 807-810,  
            818-819  
    microvascular involvement in,  
        813-814  
    muscle function and, 816-819  
    T-cell receptors in, 806-807  
    T-cell responses in, 806
- pathology of, **781-802**
- probable or possible, diagnosis of, 734
- prognosis for, 995-997
- subgroups of, clinical features of, 827
- survival in, 996
- treatment of, **979-1001**  
    apheresis in, 991  
    corticosteroids in, 984, 986-987  
    cytokines in, 991-992  
    evaluation of, 980  
    immune globulin in, 990-991, 994  
    immunosuppressive agents in,  
        987-990  
    in constitutional symptoms, 993  
    in gastrointestinal disorders, 994  
    in pulmonary disease, 992-993  
    in rash, 993-994  
    in skin disorders, 993-994  
    new techniques for, 997  
    physical therapy in, 982-984  
    principles of, 979-982  
    rehabilitation in, 982-984  
    tumor necrosis factor inhibitors in,  
        991-992  
    versus dysferlin deficiency, 744-747  
    versus dystrophic myopathy, **743-758**  
    versus merosin deficiency, 747-748,  
        750-752  
    versus metabolic myopathies. *See*  
        Metabolic myopathy(ies).
- Infliximab**  
    for juvenile rheumatoid arthritis,  
        522-523  
    for pediatric rheumatic diseases, 473  
    for spondyloarthritis, 548-549
- Influenza virus**, for myositis induction,  
    927-928
- Insulin-like growth factor-1 deficiency**, in  
    fibromyalgia syndrome, 395-396
- Insurance**, for disabled young adults, 689
- Interferon(s)**, genes for, in rheumatoid  
    arthritis, 82
- Interferon alfa**, inflammatory myopathy related  
    to, 903
- Interferon- $\gamma$**   
    for scleroderma therapy, 612  
    in inflammatory myopathy  
        pathogenesis, 809
- Interleukin(s)**  
    genes for, in rheumatoid arthritis, 82  
    in hypothalamic-pituitary-adrenal axis  
        regulation, fibromyalgia syndrome  
        and, 393  
    in inflammatory myopathy, 809,  
        811-813, 817-818, 898-899  
    produced by dendritic cells, 160-161  
    produced by T helper cells, in  
        inflammation, 156-159
- Interleukin-1**, gene therapy directed to, for  
    rheumatoid arthritis, 129-132, 136-138
- Interleukin-1 receptor antagonist**, recombinant,  
    for pediatric rheumatic diseases, 473
- Interleukin-4**, gene therapy directed to, for  
    rheumatoid arthritis, 130, 134-138

- Interleukin-10, gene therapy directed to, for rheumatoid arthritis, 130, 133-134, 136-138
- International Associations for Rheumatology, spondyloarthritides classification of, 534-535
- International League of Associations for Rheumatology, juvenile rheumatoid arthritis classification of, 504-506
- International Myositis Outcome Assessment Collaborative Study Group. *See* Inflammatory myopathy(ies), assessment of.
- Interstitial cystitis, in fibromyalgia syndrome, 314, 410, 414
- Interstitial lung disease  
in inflammatory myopathy, 832, 876, 992-993  
in juvenile dermatomyositis, 851
- Irritable bladder syndrome, in fibromyalgia syndrome, 193, 280, 410, 414-415
- Irritable bowel syndrome, in fibromyalgia syndrome, 192-193, 206, 280, 314, 409-410, 414
- Isotretinoin, for dermatomyositis, 994

---

**J**

- Jo-1 antigen, antibodies to, in inflammatory myopathy, 868, 873-878
- Jobs, in transitions for children with special health care needs and disabilities, 691-696
- Juvenile Arthritis Functional Assessment Report, 495
- Juvenile Arthritis Functional Status Index, 495
- Juvenile Arthritis Quality of Life Questionnaire, 515
- Juvenile dermatomyositis, **577-600, 837-860**  
amyopathic, 853-854  
arthritis in, 851  
cancer and, 853  
cardiac involvement in, 851-852  
chronic changes in, 589-593  
classification of, 838-840  
clinic for, in Toronto, 838  
clinical features of, 841-853  
course of, 588-589  
demographics of, 581-582  
diagnostic criteria for, 838-840  
environmental factors in, 582-583  
epidemiology of, 581-586, 840-841  
evaluation of, 589  
familial, 894  
gastrointestinal involvement in, 850  
genetic factors in, 583-588, 751, 753  
hematologic changes in, 588  
imaging in, 490  
immune response in, 586-588  
infectious agents in, 584-586  
neurologic disorders in, 851  
ophthalmologic involvement in, 852-853  
outcomes of, 854-855  
pathophysiology of, 586-588  
pulmonary involvement in, 850-851  
skin changes in, 841-842, 844-850  
susceptibility to, 583-584  
treatment of, 593, 856-857  
ulcerative course, 848-849  
versus juvenile polymyositis, 853
- Juvenile Dermatomyositis Disease Activity Score, 954
- Juvenile idiopathic arthritis, classification of, 504-506
- Juvenile polymyositis, 853
- Juvenile rheumatoid arthritis, **503-530**  
bone metabolism in, 658-661  
classification of, 503-506  
coping with, 496  
definition of, 503  
differential diagnosis of, 483-490, 509-513  
epidemiology of, 507-508  
genetic factors in, 508-509  
growth disturbances in, 516  
health-related quality of life in, 495-498, 514-515  
imaging in, 483-490  
macrophage activation syndrome in, 518-519  
mortality in, 515-516  
osteoporosis in, 516-518, 658-661  
outcome of, 513-516  
pain in, 496  
prognosis for, 515  
psychosocial adjustment in, 497  
refractory, treatment of, 523  
social functioning in, 497-498  
treatment of, 519-523

---

**K**

- Kawasaki disease, 628-635  
cardiac involvement in, 632-633  
clinical manifestations of, 630-632  
diagnosis of, 633-634  
differential diagnosis of, 632  
epidemiology of, 628

- etiology of, 628-630  
recurrent fever in, 635  
treatment of, 465-466, 634-635
- Ketamine, for fibromyalgia syndrome, 269, 344-347
- Kidney  
systemic lupus erythematosus  
manifestations in, 561-563  
vasculitis of  
in Henoch-Schönlein purpura, 640, 643-644  
in microscopic polyangiitis, 646
- KL-6 (glycoprotein), measurement of, in inflammatory myopathy, 953
- Knee, meniscal injury of, in fibromyalgia syndrome, 307
- KS antigen, antibodies to, in inflammatory myopathy, 868, 874
- Ku antigen, antibodies to, in inflammatory myopathy, 869, 883
- L**
- Lactate, measurement of, in metabolic myopathy, 769
- Lactate dehydrogenase, measurement of, in inflammatory myopathy, 949-950
- Laminin  $\alpha 2$  (merosin) deficiency, myopathy in, versus inflammatory myopathy, 747-748, 750-752
- Leflunomide  
for juvenile rheumatoid arthritis, 521  
for pediatric rheumatic diseases, 476
- Leg length discrepancy, in juvenile rheumatoid arthritis, 516
- Leukemia  
musculoskeletal pain in, 674-675  
transcript array analysis of, 163-164
- Likert scale, in inflammatory myopathy, 963
- Limb—girdle muscular dystrophy type 2B, versus inflammatory myopathy, 744-747
- Linear scleroderma, in pediatric patients, 607
- Linkage analysis  
for rheumatoid arthritis susceptibility loci search, 6-7  
in osteoarthritis, 100-107  
in systemic lupus erythematosus, 115-121
- Linkage disequilibrium, in rheumatoid arthritis, 40, 72
- Lipid metabolism, disorders of, myopathy in, 767-768
- Lipodystrophy, in dermatomyositis  
juvenile, 849  
partial, 591-593
- LJP 394, for nephritis, in systemic lupus erythematosus, 562-563
- Logarithm of odds scores, for susceptibility loci search  
in rheumatoid arthritis, 7  
in systemic lupus erythematosus, 116-121
- Lung  
computed tomography of, in inflammatory myopathy, 953  
Henoch-Schönlein purpura  
manifestations in, 641  
interstitial disease of  
in inflammatory myopathy, 832, 876, 992-993  
in juvenile dermatomyositis, 851  
systemic sclerosis manifestations in, 680-681
- Lupus. *See* Systemic lupus erythematosus.
- Lyme disease  
fibromyalgia syndrome and, 411-412, 414  
myositis in, 908
- Lymphadenopathy, in Kawasaki disease, 630
- Lymphoma, transcript array analysis of, 163-164
- M**
- McArdle's disease, clinical features of, 763, 766
- Macrophage activation syndrome, in juvenile rheumatoid arthritis, 518-519
- Macrophagic myofasciitis, in vaccination, 904
- Magnetic resonance imaging  
in inflammatory myopathy, 955  
in metabolic myopathy, 771  
in scleroderma, 609  
in systemic lupus erythematosus, 565
- Magnetic resonance spectroscopy, in inflammatory myopathy, 958
- Magnetic therapy, for fibromyalgia syndrome, 301
- Major histocompatibility complex molecules  
in inflammatory myopathy, 784, 787, 789, 791-792, 795, 797, 799, 807-810, 818-819  
in juvenile rheumatoid arthritis, 508-509

- Malignant melanoma, transcript array analysis of, 165
- Manipulation, for fibromyalgia syndrome, 300
- Massage, for fibromyalgia syndrome, 300, 358
- Mastery experiences, in fibromyalgia syndrome treatment, 292-293
- Mechanic's hands, in dermatomyositis, 849-850, 877
- Medicaid, for disabled young adults, 689
- Medical Research Council War Memorandum scale, for strength testing, in inflammatory myopathy, 941, 945
- Mediterranean fever, familial, in pediatric patients, 647-648
- Melanoma, transcript array analysis of, 165
- Melatonin, fibromyalgia syndrome and, 360, 398-399
- Membrane attack complex, in inflammatory myopathy, 792
- Menstrual cycle, fibromyalgia syndrome manifestations and, 397
- Merosin deficiency, myopathy in, versus inflammatory myopathy, 747-748, 750-752
- Metabolic myopathy(ies), **759-779**  
    biochemistry of, 769-771  
    carbohydrate metabolism in, 759-764  
    clinical features of, 761, 763-764  
    diagnosis of  
        clinical approaches to, 769-771  
        genetic approaches to, 774-775  
        pathologic approaches to, 771-774  
    differential diagnosis of, 763, 765-769  
    electron microscopy of, 774  
    genetics of, 774-775  
    glycogenoses, 763, 766-767, 774  
    histochemistry of, 773-774  
    histology of, 772-773  
    in lipid disorders, 767-768  
    mitochondrial  
        clinical features of, 768-769  
        genetics of, 775  
        histology of, 772-773  
    pathology of, 771-774
- Methadone, for fibromyalgia syndrome, in sleep disorders, 189
- Methotrexate  
    for dermatomyositis, 994  
    for inflammatory myopathy, 988-990  
    for pediatric rheumatic diseases, 466-468  
    dermatomyositis, 593, 856
- juvenile rheumatoid arthritis, 520-521
- scleroderma, 678
- spondyloarthritides, 548-549
- N-Methyl-D-aspartate receptor antagonists, for fibromyalgia syndrome, 186, **343-351**  
    dextromethorphan, 344-345, 347-348  
    ketamine, 344-347  
    mechanism of action of, 343  
    opioids with, 347-348
- Methylphenidate, for fibromyalgia syndrome, 372
- Methylprednisolone  
    for inflammatory myopathy, 987  
    for pediatric rheumatic diseases, 470  
        juvenile rheumatoid arthritis, 519-520, 523  
    Kawasaki disease, 635
- Mi-I antigen, antibodies to, in inflammatory myopathy, 869, 879-881
- Microarrays, in transcript array analysis. *See* Transcript array analysis.
- Microsatellite instability, in rheumatoid arthritis, 85-86
- Microscopic polyangiitis, in pediatric patients, 646
- Migraine headache  
    in fibromyalgia syndrome, 280-281, 313-314, 411  
    substance P inhibitors for, 337-338
- Mirtazipine, for fibromyalgia syndrome, 247, 275
- Mitochondrial myopathies  
    clinical features of, 768-769  
    genetics of, 775  
    histology of, 772-773
- Mitral valve prolapse, in fibromyalgia syndrome, 408
- Miyoshi myopathy, versus inflammatory myopathy, 744-747
- MJ antigen, antibodies to, in inflammatory myopathy, 870, 884
- MK869 (substance P inhibitor), clinical applications of, 336-337
- Moclobemide, for fibromyalgia syndrome, 247, 372
- Modafinil, for fibromyalgia syndrome, 279-280, 372, 426
- Modeling, in fibromyalgia syndrome treatment, 293



- Modified Convery Assessment, in inflammatory myopathy, 948
- Monoamine oxidase inhibitors, for fibromyalgia syndrome, 372
- Mood disorders, in fibromyalgia syndrome, 278-279
- Mucocutaneous lymph node syndrome. *See* Kawasaki disease.
- Multidimensional Pain Inventory, in fibromyalgia syndrome, 223, 225-226
- Multidisciplinary approach, to fibromyalgia syndrome treatment, 299
- Multiple sensitivities, in fibromyalgia syndrome, 193, 206, 282, 421
- Multiple sleep latency test, in fibromyalgia syndrome, 357
- Muscle(s)
- biopsy of
    - in inflammatory myopathy, 781-802, 959, 962
      - major pathologic alterations in, 782-789
      - pitfalls in, 789-791
      - specific pathologic features in, 791-799
      - specimen handling for, 781-782
    - in metabolic myopathy, 771-774
  - damage of, assessment of, in inflammatory myopathy, 962-966
  - enzyme activity of, in inflammatory myopathy, 948-950
  - extraskeletal, activity of, in inflammatory myopathy, 950-954
  - gene therapy directed to, in rheumatoid arthritis, 142-143
  - homogenates of, for myositis induction, 923, 925
  - inflammation of. *See* Inflammatory myopathy(ies); Juvenile dermatomyositis.
  - protection of, during exercise, for fibromyalgia syndrome, 421
  - strength of, in inflammatory myopathy assessment, 941-942, 945-946
  - weakness of. *See* Weakness.
- Muscular dystrophy, versus inflammatory myopathy, 746-747, 749-750, 753-756
- Musculoskeletal pain, in pediatric patients, 667-683
  - assessment of, 496, 677
  - back, 490, 671-672
  - clinical features of, 670-672
  - differential diagnosis of, 673-677
  - diffuse, 668, 671
  - epidemiology of, 669
  - etiology of, 669-670
  - idiopathic, 668
  - laboratory findings in, 672-673
  - localized, 668, 671
  - natural history of, 679-680
  - pathophysiology of, 667-668
  - prognosis for, 679-680
  - treatment of, 678-679
- Mutations, somatic, in rheumatoid arthritis, 84-85
- Myalgia, in inflammatory myopathy, 831
- Mycophenolate mofetil
  - for inflammatory myopathy, 989
  - for nephritis, in systemic lupus erythematosus, 562-563
  - for pediatric rheumatic diseases, 467, 475-476
- Myeloid cells, transcript array analysis of, 160-161
- Myocardial infarction, in juvenile dermatomyositis, 852
- Myocarditis, in inflammatory myopathy, 953-954
- Myofascial pain, 675
  - in fibromyalgia syndrome, 311-312, 407, 413
- Myofasciitis, macrophagic, in vaccination, 904
- Myoglobin, measurement of
  - in inflammatory myopathy, 949-950
  - in metabolic myopathy, 769
- Myopathy
  - dystrophic. *See* Dystrophic myopathy.
  - inflammatory. *See* Inflammatory myopathy(ies).
  - metabolic. *See* Metabolic myopathy(ies).
  - Miyoshi, versus inflammatory myopathy, 744-747
- Myosin, for myositis induction, 925-926
- Myositis. *See also* Dermatomyositis; Polymyositis.
  - animal models of, 919-935
    - inclusion body, 930
    - induced, 922-928
      - with C protein, 925-926
      - with dendritic cells, 926
      - with muscle homogenates, 923, 925
      - with myosin, 925-926
      - with naked DNA, 926-927

- with viruses, 927-928
  - spontaneous, 919-922
  - transgenic mouse, 928-931
  - cancer-related, 833
  - familial, 894
  - in eosinophilia myalgia syndrome, 903-904
  - inclusion body. *See* Inclusion body myositis.
  - orbital, 894
- Myositis Damage Index, 962-963
- Myositis Disease Activity Assessment Tool, 950-951, 954
- Myositis Functional Index, 946-947
- Myositis-specific autoantibodies, in myopathy, 814-816, 994-995
- N**
- 
- Nail fold capillaries, abnormal
- in dermatomyositis, 844-846
  - in inflammatory myopathy, 951
  - in systemic sclerosis, 614
- Naproxen
- for fibromyalgia syndrome, 266
  - for pediatric rheumatic diseases, 465-466
- Nausea, substance P inhibitors for, 336
- Nefazodone, for fibromyalgia syndrome, 247, 275
- Neopterin, in dermatomyositis, 587
- Nephritis
- in Henoch-Schönlein purpura, 640, 643-644
  - in systemic lupus erythematosus, 561-563
- Nerve growth factor inhibitors, for fibromyalgia syndrome, 186-187, 269
- Neurokinin-1 receptor
- antagonists of, 334-339
  - clinical applications of, 336-339
  - for fibromyalgia syndrome, 339
  - structures of, 335
  - characteristics of, 332-334
- Neurologic disorders
- in juvenile dermatomyositis, 851
  - in systemic lupus erythematosus, 563-565
- Neuromuscular Symptom and Disability Functional Score, in inflammatory myopathy, 948
- Neuropathic pain, in fibromyalgia syndrome, 313

- Neuropharmacology, of analgesics, for fibromyalgia syndrome, 235-259
- antidepressants, 244-247
  - antiepileptic drugs, 248-249
  - antispastic drugs, 249
  - opiates, 248
  - pain pathways and, 236-244
- Neurotransmitters, in pain transmission, 239-244
- Nicotinamide adenine dinucleotide, for fibromyalgia syndrome, 373-374
- Nitric oxide, genotoxicity of, in rheumatoid arthritis, 83-84
- Nociception, 330
- in fibromyalgia syndrome, 236-244
- Nodules, in polyarteritis nodosa, 635-637
- Nonsteroidal anti-inflammatory drugs
- for fibromyalgia syndrome, 268, 426
  - for pediatric rheumatic diseases, 465-466
  - Henoch-Schönlein purpura, 642
  - juvenile rheumatoid arthritis, 519-520
  - spondyloarthritis, 548
- Norepinephrine, in pain transmission, 241-243
- Norepinephrine reuptake inhibitors, for fibromyalgia syndrome, 247
- Nortriptyline, for fibromyalgia syndrome, 274
- NSAIDs. *See* Nonsteroidal anti-inflammatory drugs.
- Nutrition
- in pediatric rheumatic diseases, 461-462
  - inflammatory myopathy related to, 902-904
- O**
- 
- OJ antigen, antibodies to, in inflammatory myopathy, 868, 874
- Oligoarthritis, in juvenile rheumatoid arthritis
- classification, 505
- Oligonucleotides, in transcript array analysis.
- See* Transcript array analysis.
- Omeprazole, for esophagitis, in systemic sclerosis, 617
- Ondansetron, for fibromyalgia syndrome, 320-321
- Ophthalmologic disorders, in juvenile dermatomyositis, 852-853

- Opioids, for fibromyalgia syndrome, 248, 271-273  
 exercise implications of, 425  
 in sleep disorders, 361  
 N-methyl-D-aspartate receptor antagonists with, 347-348
- Oral cavity, juvenile dermatomyositis involvement of, 849-850
- Orbital myositis, 894
- Orthostatic hypotension, in fibromyalgia syndrome, 380-384, 408
- Osteoarthritis  
 in fibromyalgia syndrome, 306  
 primary, genetics of, **95-109**  
 early-onset, 100-102  
 genome-wide scan in, 105-107  
 linkage analysis in, 100-107  
 segregation studies in, 99-100  
 sibling studies in, 98-99, 102-107  
 twin studies in, 96-97
- Osteoblasts, in bone metabolism, 654
- Osteocalcin, as bone metabolism marker, 655
- Osteoclasts, in bone metabolism, 654
- Osteocytes, physiology of, 654
- Osteomyelitis, recurrent multifocal, musculoskeletal pain in, 675
- Osteoporosis, in pediatric rheumatic diseases, 463-464  
 bone density measurement in, 567, 657-658  
 bone physiology and, 653-654  
 definition of, 655-656  
 idiopathic juvenile, 676-677  
 juvenile rheumatoid arthritis, 516-518  
 systemic lupus erythematosus, 566-568  
 treatment of, 470-471  
 versus normal bone growth, 656-657
- P**
- p53* gene mutations, in rheumatoid arthritis, 84-85
- Pain  
 in fibromyalgia syndrome  
 analgesics for, **235-259**  
 bursitis, 310  
 central pathways for, 236-244, 266  
 chest, 408-409, 413  
 costochondritis, 310  
 descending inhibitory/facilitatory system of, 270-271  
 dorsal horn sensitization in, 268-269  
 endocrine interactions with, 389-404  
 enthesopathies, 307, 309-310  
 entrapment neuropathies, 313  
 epicondylitis, 307-308  
 evaluation of, 202-203  
 exercise-related, 430-431  
 from concomitant conditions, 208-209  
 headache. *See* Headache.  
 5-HT<sub>3</sub> receptor antagonists for, **319-328**  
 interstitial cystitis, 314, 410, 414  
 mechanisms of, 183-187, 305  
 meniscal injury, 307  
 N-methyl-D-aspartate receptor antagonists for, **343-351**  
 myofascial, 308-309, 311-312, 407  
 neuropathic, 313-314  
 opioids for. *See* Opioids.  
 osteoarthritis, 306-307  
 pelvic, 410-411, 414-415  
 periostitis, 307  
 peripheral generators of, 267-268, **305-317**  
 physiologic targets for, 267  
 plantar fasciitis, 310  
 post-exercise, 190-191  
 psychological aspects of, 220-221  
 radiculopathy, 313  
 reflex sympathetic dystrophy, 408-409, 414  
 soft tissue, 310-312  
 supraspinal influences on, 269-270  
 temporomandibular joint, 281, 407, 413  
 tendinitis, 310  
 treatment of, 183-187, 265-277  
 visceral, 314  
 musculoskeletal. *See* Musculoskeletal pain.  
 somatic, substance P inhibitors for, 338-339
- Pamidronate, for osteoporosis  
 in juvenile rheumatoid arthritis, 518  
 in pediatric rheumatic diseases, 471  
 in spondyloarthritides, 548-549
- Pan sclerotic morphea of childhood, 608
- Parasitic infections, inflammatory myopathy in, 907-908
- Paresthesia, in fibromyalgia syndrome, 205, 313
- Paroxetine, for fibromyalgia syndrome, 275, 424
- Parry Romberg syndrome, 603-604, 607-608

- Parvovirus B19 infections  
inflammatory myopathy and, 908-909  
systemic lupus erythematosus and, 568
- Patient education, on fibromyalgia syndrome, 295-296, 368-370, 439-441
- Pediatric Evaluation of Disability Inventory, in inflammatory myopathy, 948
- Pediatric patients, rheumatic diseases in  
back pain in, 490, 671-672  
bone metabolism in, **653-665**  
dermatomyositis. *See* Juvenile dermatomyositis.  
differential diagnosis of, imaging in, **483-492**  
extremity abnormalities in, imaging in, 487-488  
fever in, imaging in, 484-487  
gait abnormalities in, imaging in, 488-490  
health-related quality of life with, **493-501**, 514-515  
imaging in, for differential diagnosis, **483-492**  
juvenile rheumatoid arthritis. *See* Juvenile rheumatoid arthritis.  
musculoskeletal pain syndromes, **667-683**  
scleroderma, 490, **601-622**  
spondyloarthritis, **531-557**, 673-674  
systemic lupus erythematosus, **559-576**  
transitions in, **685-701**  
treatment of, **461-482**  
    biologicals in, 471-473  
    bone development and, 462-463  
    corticosteroids in, 469-470. *See also* Corticosteroids, for specific diseases.  
    growth considerations in, 462-463  
    immune response and, 463-465  
    immunosuppressive, 473-476. *See also* specific drugs.  
    NSAIDs in. *See* Nonsteroidal anti-inflammatory drugs, for pediatric rheumatic diseases.  
    nutrition in, 461-462  
    slow-acting drugs in, 466-469  
    vasculitis, 490-491, **623-651**
- Pediatric Quality of Life Inventory, in inflammatory myopathy, 967
- Pediatric Rheumatology International Trials Organization collaborative effort. *See* Inflammatory myopathy(ies), assessment of.
- Pelvic pain, in fibromyalgia syndrome, 410-411, 414-415
- D-Penicillamine, inflammatory myopathy related to, 902-903
- Perforin, in inflammatory myopathy, 810, 815
- Periaqueductal gray matter, pain transmission in, 241-243
- Periodic involuntary arousal, in fibromyalgia syndrome, 355
- Periodic involuntary limb movements, in fibromyalgia syndrome, 355, 360-361
- Periodic K $\alpha$  disorder, in fibromyalgia syndrome, 355
- Periostitis, in fibromyalgia syndrome, 307
- Peripheral mononeuropathy, musculoskeletal pain in, 676
- Peripheral pain generators, in fibromyalgia syndrome, 185-186, 267-268, **305-317**  
classification of, 306  
definition of, 305  
treatment of, 306-314
- Pernio, musculoskeletal pain in, 676
- Photochemotherapy, for scleroderma, 612
- Physical therapy  
for idiopathic musculoskeletal pain, 678  
for inflammatory myopathy, 982-984  
for scleroderma, 678
- Physical training. *See* Exercise.
- Picornaviruses  
for myositis induction, 927  
inflammatory myopathy related to, 905-906
- Piriformis muscle, sciatic nerve entrapment at, in fibromyalgia syndrome, 313
- Pirlindole, for fibromyalgia syndrome, 247
- Pituitary gland dysfunction, in fibromyalgia syndrome, 391-394
- PL-7 antigen, antibodies to, in inflammatory myopathy, 868, 874
- PL-12 antigen, antibodies to, in inflammatory myopathy, 868, 874, 876-877
- Plantar fasciitis, in fibromyalgia syndrome, 310
- Plaque morphea, in pediatric patients, 608
- Plasmapheresis, for inflammatory myopathy, 991
- Plastic surgery, for scleroderma, 679

- PM-Scl antigen, antibodies to, in inflammatory myopathy, 869, 881-882
- PMS1 autoantigen  
antibodies to, in inflammatory myopathy, 870, 884  
in inflammatory myopathy, 815
- Pneumococcal infections, in systemic lupus erythematosus, 568-569
- Poikilodermatous rash, in dermatomyositis, 846-847
- Polyangiitis, microscopic, in pediatric patients, 646
- Polyarteritis nodosa, in pediatric patients, 635-637
- Polyarthritis, in juvenile rheumatoid arthritis classification, 505
- Polymyositis  
animal models of. *See* Myositis, animal models of.  
arthralgia in, 833  
autoantibodies in. *See* Inflammatory myopathy(ies), autoantibodies in.  
cancer in, 833  
diagnostic criteria for, 736-737  
epidemiology of, 727  
familial, 894  
histochemistry of, 795-797  
immunopathology of, 797, 799  
infantile (merosin deficiency), versus inflammatory myopathy, 747-748, 750-752  
juvenile, 853  
pathology of, 784, 786-787, 789-790, 795-799  
pulmonary involvement in, 832  
retrovirus infections with, 799  
weakness in, 832
- Polysomnography, in fibromyalgia syndrome, 356-357
- Pompe's disease, clinical features of, 767
- Postural hypotension, in fibromyalgia syndrome, 380-384, 408
- Pramipexole, for fibromyalgia syndrome, in sleep disorders, 361
- Prednisolone, for inflammatory myopathy, 986
- Prednisone  
for fibromyalgia syndrome, 266, 281, 394  
for Henoch-Schönlein purpura, 642, 644  
for inflammatory myopathy, 984, 986-987  
for spondyloarthritis, 548-549
- Pregabalin, for fibromyalgia syndrome, 249
- Primary afferent fibers, pain transmission in, in fibromyalgia syndrome, 237-240
- Primary angitis, of central nervous system, 627-628
- Procollagen, peptides of, as bone metabolism marker, 655
- Progressive diaphyseal dysplasia, musculoskeletal pain in, 676
- Prolactin, excess of, in fibromyalgia syndrome, 398
- Propranolol, for fibromyalgia syndrome, 385, 425-426
- Pseudoscleroderma, 682
- Psoralen, for scleroderma, 678
- Psoriasis, transcript array analysis of, 171
- Psoriatic arthritis, juvenile-onset, 506, 544-545
- Psychiatric disorders, in systemic lupus erythematosus, 563-565
- Psychological factors  
in fibromyalgia syndrome  
evaluation of, 204, 207, **219-233**  
areas addressed in, 228, 230-231  
components of, 227-229  
example of, 223, 225-226  
instruments for, 222, 224-225  
preparation for, 226-227  
purposes of, 222-223  
referral for, 226-228  
screening in, 222  
treatment related to, 189-190, 270, 278-279  
in idiopathic musculoskeletal pain, 669, 672, 677
- Psychosocial adjustment, in arthritis, quality of life and, 497
- Psychotherapy, for idiopathic musculoskeletal pain, 678
- Pulmonary function  
in Henoch-Schönlein purpura, 641  
in systemic sclerosis, 680-681  
testing of, in inflammatory myopathy, 950, 952
- Purpura, Henoch-Schönlein.  
*See* Henoch-Schönlein purpura.

**Q**

Qu Gong, for fibromyalgia syndrome, 298

Quality of life

health-related. *See* Health-related quality of life.

in fibromyalgia syndrome, evaluation of, 204, 207-208

Quinacrine, for dermatomyositis, 994

**R**

Radiculopathy, in fibromyalgia syndrome, 313

Rash

in dermatomyositis, 827-831, 841, 844, 846-847, 993-994

in Kawasaki disease, 630-631

in psoriatic arthritis, 544-545

Raynaud phenomenon

in inflammatory myopathy, 877

in systemic sclerosis, 614

primary, musculoskeletal pain in, 675

Reactive arthritis, 542-543

Reflex sympathetic dystrophy, in fibromyalgia syndrome, 408-409, 414

Rehabilitation, in inflammatory myopathy, 982-984

Reiter's syndrome, 542-543

Respiratory disorders

in Henoch-Schönlein purpura, 641

in inflammatory myopathy, 832, 992-993

in juvenile dermatomyositis, 850-851

in systemic sclerosis, 680-681

Restless legs syndrome, in fibromyalgia syndrome, 206, 278, 355, 361-362, 410

Retinopathy, in juvenile dermatomyositis, 852-853

Retroviruses

genetic effects of, in rheumatoid arthritis, 87-88

inflammatory myopathy and, 799, 906-907

Reversible, enzyme-specific

monoamine-oxidase inhibitors, for fibromyalgia syndrome, 246-247

Rheumatoid arthritis

arthritogenic peptides in, 22

clinical features of, human leukocyte antigens and, 18-19, 24-25

epidemiology of, genetic considerations in, 18

erosive synovitis in, human leukocyte antigens and, 18-19, 25-31

ethnic differences in, 19-20, 42-45  
shared epitope hypothesis and, 62-67

extra-articular manifestations of, human leukocyte antigens and, 25

fibromyalgia syndrome with, 409

gender differences in, human leukocyte antigens and, 24, 43, 47

gene therapy for, 127-149

chondrocyte-directed, 141-142

controlled expression in, 143

gene targets for, 127-128

interleukin-1-directed, 129-132, 136-138

interleukin-4-directed, 130, 134-138

interleukin-10-directed, 130,

133-134, 136-138

muscle-directed, 142-143

precautions with, 143-144

remote effects of, 136-140

side effects of, 143-144

synovium-directed, 139-140

T-cell-directed, 140-141

tissue targets for, 139-143

tumor necrosis factor-directed, 131-132, 136-138

genetics of, 1-15

affected sibling pair studies in, 3, 7-9

candidate gene approach to, 5-6

challenges in, 12-13

epistasis (gene-gene interactions) in, 72

gene contribution, 2-4

heterogeneity and, 39-58

human leukocyte antigen and. *See* Human leukocyte antigens, in rheumatoid arthritis.

linkage methods in, 6-7

outcome and, 39-58

predictive power, 1-2

prognosis and, 17-37

shared epitope hypothesis for. *See* Shared epitope hypothesis.

susceptibility, 1-2

target tissue and, 79-94

chromosomal shortening,

86-87

dedifferentiated, 88-89

genotoxicity, 83-84

human leukocyte antigen

associations in, 79-81

microsatellite instability,

85-86

non-germline associations in,

83-86

- non-HLA-associated alleles
    - in, 81-82
    - retroviral effects on, 87-88
    - somatic mutations, 84-85
    - versus nongenetic component, 4-5
  - heterogeneity of, human leukocyte antigens and, 39-58
    - case-control studies of, 42-50
    - cohort studies of, 50-52
    - risk factors for, 39-41
  - human leukocyte antigens in. *See* Human leukocyte antigens, in rheumatoid arthritis.
  - juvenile. *See* Juvenile rheumatoid arthritis.
  - linkage disequilibrium in, 72
  - outcome of, human leukocyte antigens and, 39-58
    - case-control studies of, 42-50
    - cohort studies of, 50-52
  - pathogenesis of, immunology of, 21-23
  - prevalence of, 3-4
  - prognosis for, genetic considerations in, 18, 23-24
  - rheumatoid factor in, human leukocyte antigens and, 24-25, 49-50
  - shared epitopes in. *See* Shared epitope hypothesis.
  - T-lymphocyte receptor repertoire in, 22-23
  - transcript array analysis of, 167-169
  - treatment of
    - gene therapy in, 127-149
    - response to, human leukocyte antigen markers in, 31-32
    - shared epitope hypothesis and, 66-67
  - Rheumatoid factor, in rheumatoid arthritis, human leukocyte antigens and, 24-25, 49-50
  - Rickets, musculoskeletal pain in, 677
  - Rider classification, of inflammatory myopathies, 840
  - RNP antibodies, in systemic lupus erythematosus, 569
  - Ro/SSA antigen, antibodies to, in inflammatory myopathy, 869, 882-883
  - Rostral ventromedial medulla, pain transmission in, 241-243
- S**
- Sacroiliac joint, arthritis of, in ankylosing spondylitis, 543-544
  - Salmonella* infections, reactive arthritis in, 542-543
  - Sarcoidosis, vasculitis in, 647
  - Scintigraphy, in inflammatory myopathy, 958
  - Scleroderma
    - in pediatric patients, 601-622
      - imaging in, 490
      - localized, 601-613
        - classification of, 602-604
        - clinical features of, 605-608
        - diagnosis of, 608-609
        - en coup de sabre, 602-604, 607
        - epidemiology of, 604-605
        - extracutaneous involvement in, 608
        - historical aspects of, 602
        - linear, 607
        - outcome of, 609-610
        - pan sclerotic morphea of childhood, 608
        - Parry Romberg syndrome, 603-604, 607-608
        - pathology and pathogenesis of, 610-612
        - plaque morphea, 608
        - subtypes of, 605-608
        - treatment of, 612-613
        - versus systemic sclerosis, 681-682
      - transcript array analysis of, 169-170
    - Sclerosis, systemic, in pediatric patients, 613-617
    - SEA (seronegative enthesopathy and arthropathy) syndrome, 540-542
    - Segregation studies, in osteoarthritis, 99-100
    - Selective serotonin reuptake inhibitors, for fibromyalgia syndrome, 244, 246, 273-275, 279, 371-372, 424, 442
    - Self-efficacy, in fibromyalgia syndrome treatment, 292-294
    - Sensitization mechanisms, in fibromyalgia syndrome pain, 235-244, 421
    - Septic arthritis, versus juvenile rheumatoid arthritis, 509-512
    - Seronegative arthritides, transcript array analysis of, 171
    - Seronegative enthesopathy and arthropathy (SEA) syndrome, 540-542
    - Serotonin, in pain transmission, 241-243
    - Serotonin-norepinephrine dual reuptake inhibitors, for fibromyalgia syndrome, 246
    - Sertraline, for fibromyalgia syndrome, 275

- Sex hormones  
  fibromyalgia syndrome related to,  
    396-398  
  in systemic lupus erythematosus  
    development, 560-561
- Sexual function, in fibromyalgia syndrome,  
  evaluation of, 208
- Shared epitope hypothesis, for rheumatoid  
  arthritis severity, 19, 22, 40, 47-48,  
    59-78  
  allele variations and, 70  
  epistasis and, 72  
  ethnic differences in, 62-67  
  inadequate power in studies of, 68-69  
  linkage disequilibrium and, 72  
  principles of, 60-62  
  severity measures and, 67-68  
  target tissue considerations in, 81  
  treatment response and, 66-67
- Shawl-sign rash, in dermatomyositis, 829
- Shigella* infections, reactive arthritis in, 542
- Short stature, in juvenile rheumatoid  
  arthritis, 516
- Sibling studies  
  in osteoarthritis, 98-99, 102-107  
  in rheumatoid arthritis, 3, 7-9  
  in systemic lupus erythematosus,  
    115-121
- Signal recognition particle, antibodies to  
  in inflammatory myopathy, 868-869,  
    878-879  
  in myopathy, 815, 994-995
- Silica, inflammatory myopathy related to, 904
- Silicone gel, inflammatory myopathy related  
  to, 905
- Single photon emission computed tomography,  
  in systemic lupus erythematosus, 565
- Sjögren's syndrome, fibromyalgia syndrome  
  with, 210, 409
- Skin  
  Henoch-Schönlein purpura  
    manifestations in, 638-639  
  lesions of, in inflammatory myopathy.  
    See Dermatomyositis.  
  scleroderma of. See Scleroderma.  
  systemic lupus erythematosus  
    manifestations in, 561
- SLE. See Systemic lupus erythematosus.
- Sleep apnea, in fibromyalgia syndrome, 189,  
  356, 361-362
- Sleep disorders, in fibromyalgia syndrome,  
  353-365
- alpha-electroencephalographic  
  anomalies, 353-355, 357  
  assessment of, 356-357  
  circadian autonomic disturbance, 356  
  evaluation of, 203  
  melatonin secretion and, 360, 398-399  
  periodic involuntary arousal, 355  
  periodic involuntary limb movements,  
    355, 360-361  
  periodic K $\alpha$  disorder, 355  
  restless legs syndrome, 206, 278, 355,  
    361-362, 410  
  sleep apnea, 189, 356, 361-362  
  treatment of, 188-189, 277-278,  
    357-362, 385  
  unrefreshing, 353-355
- Smith antigens, antibodies to, in systemic lupus  
  erythematosus, 569
- snRNP antigens, antibodies to, in inflammatory  
  myopathy, 869, 882
- Social functioning, in arthritis, quality of life  
  and, 497-498
- Social persuasion, in fibromyalgia syndrome  
  treatment, 293
- Somatic genetic changes, in rheumatoid  
  arthritis, 4
- Somatic mutations, in rheumatoid arthritis,  
  84-85
- Somatic pain, substance P inhibitors for,  
  338-339
- Spinal cord  
  pain transmission in, in fibromyalgia  
    syndrome, 236-244  
  tumors of, musculoskeletal pain in, 675
- Spine, ankylosing spondylitis of, 543-544
- Spondyloarthritides, juvenile-onset, 531-557,  
  673-674  
  ankylosing spondylitis, 543-544  
  ankylosing tarsitis, 546-547  
  arthritis in, 535-537  
  classification of, 534-535  
  diagnostic criteria for, 534-535  
  enthesitis in, 537-539  
  epidemiology of, 532-534  
  in inflammatory bowel disease,  
    545-546  
  isolated forms of, 539-540  
  musculoskeletal pain in, 673-674  
  pathogenesis of, 547  
  psoriatic arthritis, 544-545  
  reactive arthritis, 542-543  
  Reiter's syndrome, 542-543  
  SEA (seronegative enthesopathy and  
    arthropathy) syndrome, 540-542



- spectrum of, 532  
treatment of, 547-549
- Spondyloarthropathy, seronegative, transcript array analysis of, 171
- Statins, inflammatory myopathy related to, 903
- Steinbrocker classification, of juvenile rheumatoid arthritis, 514
- Stem cell transplantation  
for inflammatory myopathy, 992  
for juvenile rheumatoid arthritis, 523  
for systemic sclerosis, 617
- Stimulants, for fibromyalgia syndrome, 279-280, 372
- Strength, muscle, in inflammatory myopathy assessment, 941-942, 945-946
- Strength training, for fibromyalgia syndrome, 427-428, 432-434
- Stress, in fibromyalgia syndrome. *See also* Pain.  
as aggravating factor, 206-207  
endocrine factors in, 389-404
- Stretching exercises, for fibromyalgia syndrome, 429-430, 432-434
- Substance P, 329-342  
measurement of, 331-332  
neurobiology of, 239, 330-331  
receptors for, 332-334  
antagonists of, 269, 334-339  
structure of, 335
- Sulfasalazine  
for juvenile rheumatoid arthritis, 521  
for pediatric rheumatic diseases, 467-468  
for spondyloarthritides, 548-549
- Swelling, in fibromyalgia syndrome, 205
- Sympathectomy, for idiopathic musculoskeletal pain, 678
- Sympathetic block, for idiopathic musculoskeletal pain, 678
- Synoviocytes  
dedifferentiated, in rheumatoid arthritis, 88-89  
genetics of, in rheumatoid arthritis. *See* Rheumatoid arthritis, genetics of, target tissue and.
- Synovitis, erosive, in rheumatoid arthritis, human leukocyte antigens and, 18-19, 25-31
- Synovium, gene therapy directed to, in rheumatoid arthritis, 139-140
- Synthetase, antibodies to, myopathy in, 814-816, 834, 994-995
- Systemic arthritis, in juvenile rheumatoid arthritis classification, 504
- Systemic lupus erythematosus  
fibromyalgia syndrome with, 409  
genetics of, 111-126  
linkage analysis in, 115-121  
murine models of, 112-115  
transcript array analysis in, 170-171  
in pediatric patients, 559-576  
arthritis in, 565  
central nervous system disease in, 563-565  
clinical features of, 559-565  
dermatologic manifestations of, 561  
epidemiology of, 559  
hormonal influences in, 560-561  
infections in, 568-569  
kidney involvement in, 561-563  
laboratory studies in, 569-570  
morbidity and mortality in, 565-566  
musculoskeletal complications of, 566-568  
sex influences in, 560-561  
vaccinations for, 568-569  
versus adults, 559-560
- Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, 566
- Systemic sclerosis  
in pediatric patients, 613-617  
autoantibodies in, 615  
differential diagnosis of, 615-616  
epidemiology of, 613  
esophagitis in, 615, 617  
nail fold capillary examination in, 614  
outcome of, 617  
pulmonary disease in, 614-615  
Raynaud's phenomenon in, 614  
treatment of, 616-617  
versus localized scleroderma, 681-682  
versus pseudoscleroderma, 616  
inflammatory myopathy with, 728-729

## T

- T lymphocytes  
gene therapy directed to, in rheumatoid arthritis, 140-141  
in inflammatory myopathy, 787, 789, 791, 793, 795-799, 805-807, 810  
receptors for  
defects of, in inflammatory myopathy, 899

- in inflammatory myopathy, 806-807
  - in rheumatoid arthritis, human leukocyte antigens and, 22-23
  - subsets of, in dermatomyositis, 587
  - transcript array analysis of, 155-159
- Tacrolimus, for inflammatory myopathy, 989
- Tai Chi, for fibromyalgia syndrome, 298
- Takayasu's arteritis, in pediatric patients, 626-627
- Tarsal tunnel syndrome, in fibromyalgia syndrome, 313
- Tarsitis, ankylosing, 546-547
- Tartrate-resistant acid phosphatase, as bone metabolism marker, 655
- Tarui's disease, clinical features of, 766
- Telomerase, in chromosomal shortening, in rheumatoid arthritis, 86-87
- Temporomandibular joint dysfunction, in fibromyalgia syndrome, 281, 407, 413
- Tender points, in fibromyalgia syndrome, 181-182, 210
- Tendinitis, in fibromyalgia syndrome, 310
- Tenoxicam, for fibromyalgia syndrome, 266
- Testosterone, fibromyalgia syndrome related to, 396-397
- Thalidomide, for spondyloarthritis, 548-549
- Thermography, in scleroderma, 609
- Thoracic outlet syndrome, in fibromyalgia syndrome, 313
- Thyroid disease
  - in fibromyalgia syndrome, 394-395
  - musculoskeletal pain in, 677
- Tilt table test, in fibromyalgia syndrome, 210, 380-384
- Tizanidine, for fibromyalgia syndrome, 249, 276, 278, 425
- Tolmetin, for pediatric rheumatic diseases, 465-466
- Toxoplasmosis
  - inflammatory myopathy in, 907-908
  - juvenile dermatomyositis in, 585-586
- Tramadol, for fibromyalgia syndrome, 248, 266, 273, 279, 347-348, 424
- Transcript array analysis, **151-176**
  - clustering algorithms in, 152-153
  - description of, 151
  - future of, 171-172
  - of B lymphocytes, 159-160
  - of cancer, 162-166
  - of cellular transcriptional response to infection, 161-162
  - of fibroblast cell cycle regulation, 154-155
  - of leukemia, 163-164
  - of lymphoma, 163-164
  - of malignant melanoma, 165
  - of model systems, 153-155
  - of myeloid cells, 160-161
  - of rheumatoid arthritis, 167-169
  - of scleroderma, 169-170
  - of seronegative arthritides, 171
  - of systemic lupus erythematosus, 170-171
  - of T lymphocytes, 155-159
  - of tumor susceptibility to antineoplastic agents, 166
  - of ulcerative colitis, 169
  - of yeast systems, 153-154
  - technology for, 152
- Transgenic mouse models, of myositis, 928-931
- Transitions, in children with special health care needs and disabilities, **685-701**
  - adolescent issues, 690-691
  - beginning of, 686
  - coordination of, 687
  - definition of, 686
  - education in, 691-696
  - family involvement in, 686
  - health care provider in, 687, 689-690
  - information resources for, 698-699
  - medical care in, 689-690
  - needs of, 688-689
  - principles of, 686-688
  - service models for, 696-698
  - work preparation in, 691-696
- Transplantation, stem cell
  - for inflammatory myopathy, 992
  - for juvenile rheumatoid arthritis, 523
  - for systemic sclerosis, 617
- Transposons, in rheumatoid arthritis, 87-88
- TRAPS (tumor necrosis factor-receptor associated periodic syndrome), 755, 899
- Trauma, versus juvenile rheumatoid arthritis, 510
- Trazodone, for fibromyalgia syndrome, 275, 278, 424
- Triamcinolone hexacetonide, for juvenile rheumatoid arthritis, 520

- Tricyclic antidepressants, for fibromyalgia syndrome, 244-246, 371
- Trigger points, in fibromyalgia syndrome, 311-312
- Triggering factors, for fibromyalgia syndrome, evaluation of, 204, 206-207
- Tropisetron, for fibromyalgia syndrome, 190, 250, 276-277, 320-323  
in dysautonomia, 385  
in fatigue, 279, 373
- Troponin, measurement of, in inflammatory myopathy, 949
- Trypanosoma cruzi*, inflammatory myopathy and, 908
- L-Tryptophan  
for fibromyalgia syndrome, 359-360  
inflammatory myopathy related to, 903-904
- Tumor necrosis factor- $\alpha$   
308A allele of, in juvenile dermatomyositis, 584  
gene for, in rheumatoid arthritis, 40-41, 82  
gene therapy directed to, for rheumatoid arthritis, 131-132, 136-138  
in hypothalamic-pituitary-adrenal axis regulation, fibromyalgia syndrome and, 393  
in inflammatory myopathy, 809, 811-813, 817-819  
in muscular dystrophy, 755-756  
inhibitors of  
for inflammatory myopathy, 13  
for juvenile dermatomyositis, 593  
for juvenile rheumatoid arthritis, 522-523  
for pediatric rheumatic diseases, 467, 472-473
- Tumor necrosis factor-receptor associated periodic syndrome (TRAPS), 755, 899
- Twin studies  
in osteoarthritis, 96-97  
in rheumatoid arthritis, 3

## U

- Ulcer(s), cutaneous, in dermatomyositis, 848-849
- Ulcerative colitis  
arthropathy of, 545-546  
transcript array analysis of, 169
- Ultrasonography, in inflammatory myopathy, 955, 958
- Ultraviolet light therapy, for scleroderma, 612
- Urologic motility disorders, substance P inhibitors for, 337
- 
- ## V
- Vaccination  
in rheumatic diseases, 464-465, 568-569  
inflammatory myopathy related to, 904
- Vacuolization, of muscle fiber, in inflammatory myopathy, 782, 786, 788-791, 793
- Vaginismus, in fibromyalgia syndrome, 410-411
- Valerian, for fibromyalgia syndrome, 359
- Vasculopathy and vasculitis  
in dermatomyositis, nailfold, 844-846  
in inflammatory myopathy, 813-814  
gastrointestinal, 952  
in juvenile dermatomyositis, 850, 852  
in pediatric patients, **623-651**  
antineutrophil cytoplasmic antibody-positive, 644-647  
Churg-Strauss syndrome, 646-647  
classification of, 623  
clinical evaluation of, 624-626  
differential diagnosis of, imaging in, 490-491  
familial Mediterranean fever, 647-648  
Henoch-Schönlein purpura, 638-644  
hypersensitivity, versus Henoch-Schönlein purpura, 641  
imaging in, 490-491  
Kawasaki disease, 628-635  
large vessel, 626-628  
medium vessel, 628-637  
microscopic polyangiitis, 646  
pathogenesis of, 623-624  
polyarteritis nodosa, 635-637  
primary angiitis of central nervous system, 627-628  
sarcoidosis, 647  
secondary, 647-648  
small vessel, 637-644  
Takayasu's arteritis, 626-627  
Wegener's granulomatosis, 644-646
- Venlafaxine, for fibromyalgia syndrome, 246, 274, 372
- Viruses, for myositis induction, 927-928
- Vitamin D

- deficiency of, musculoskeletal pain in, 677
- for osteoporosis
  - in juvenile rheumatoid arthritis, 518
  - in pediatric rheumatic diseases, 657
  - in systemic lupus erythematosus, 567
- for scleroderma, 612

Vomiting, substance P inhibitors for, 336

von Willebrand factor VIII related antigen, measurement of, in inflammatory myopathy, 959

Vulvodynia, in fibromyalgia syndrome, 410-411

## W

---

### Weakness

- in inflammatory myopathy, 831-832
  - causes of, 981-982
  - pathogenesis of, 816-819
- in juvenile polymyositis, 853
- in metabolic myopathy, 761, 763
  - glycogenoses, 763, 766-767
  - mitochondrial, 768-769

Wegener's granulomatosis, in pediatric patients, 644-646

Wingless and frizzled receptor ligand pair, in rheumatoid arthritis, 88

*WISP* genes, mutations of, in rheumatoid arthritis, 88-89

Work, in transitions for children with special health care needs and disabilities, 691-696

## X

---

X chromosome inactivation, in rheumatoid arthritis, 4-5

## Y

---

Yeast, transcript array analysis of, 153-154

*Yersinia* infections, reactive arthritis in, 542-543

Yoga, for fibromyalgia syndrome, 298

## Z

---

Zaleplon, for fibromyalgia syndrome, 277

Zolpidem, for fibromyalgia syndrome, 266, 277, 424

